

CEM GUIDED BIOPSY IN PRONE POSITION experience with IMS-GIOTTO CLASS SYSTEM



Dr Luc ROTENBERG

Radiologie Paris Ouest-RPO-ISHH
105 Ave Charles de Gaulle
Neuilly Sur Seine-France

dr.rotenberg@radiologieparisouest.com

With courtesy of

Dr Jacopo NORI-CUCCHIARI

Breast Imaging-Careggi University Hospital
Florence-Italy

TRAITEMENTS LOCORÉGIONAUX DES CANCERS DU SEIN INFILTRANTS NON MÉTASTATIQUES

/ synthèse

INCA OCTOBRE 2021

RECOMMANDATIONS

BILAN INITIAL

BILAN D'EXTENSION LOCALE

- Le groupe de travail rappelle que le bilan d'extension locale repose sur la mammographie bilatérale¹ et l'IRM mammaire.
- La tomosynthèse peut être proposée en complément de la mammographie bilatérale.
- En dehors des critères histologiques et biologiques de suspicion clinique de métastase axillaire ou de ganglion lymphatique régional (Grade C), une IRM mammaire peut être proposée (Grade C). La place de l'IRM dans la situation de la présence d'une atteinte axillaire isolée ou d'un ganglion lymphatique régional (Grade C) sera abordée dans une partie spécifique (partie 2 de l'expertise en cours de rédaction).
- La densité mammaire, les critères histologiques, notamment le caractère lobulaire infiltrant (Grade C), ou une indication d'oncoplastie (Avis d'experts) ne sont pas des critères qui permettent à eux seuls de poser l'indication de l'IRM mammaire.

LÉGENDE

- conduites à tenir recommandées
- conduites à tenir non recommandées ou impossibilité d'émettre une recommandation par absence de données ou données insuffisantes

pre-operative breast MRI/CESM indications Guidelines


- Facteur de risque de cancer du sein
- Femme jeune
- Seins denses
- Difficulté à évaluer le volume tumoral
- Doute quant à l'existence de lésions additionnelles
- Suspicion d'extension au muscle pectoral/paroi thoracique
- Cancer lobulaire infiltrant
- CIS diagnostiqué sur biopsie de microcalcifications
- Maladie de Paget

Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group


EUROPEAN JOURNAL OF CANCER 46 (2010) 1296–1316

- breast dense
- < 40 y
- High Risk patient > 20%
- Skin sparing mastectomy
- HER2+ and triple negative lesion
- multiple or bilaterale lesion
- DCIS unifocal (additional lesion ?)
- NAC

Comparative Performance of Contrast-enhanced Mammography, Abbreviated Breast MRI, and Standard Breast MRI for Breast Cancer Screening




- Prospective study of 246 participants who had breast MRI and CE mammography.
- Compared with MRI, CE mammography had lower recall (difference, -9%), lower false-positive biopsy recommendation (-98 per 1000 examinations), and higher specificity (difference, 8%).
- CE mammography was less sensitive (difference, -39%) and had lower cancer detection rate (difference, -14) compared with standard MRI.



Bar charts of each performance metric summarize examination-level performance by modality, with P values indicating significant differences. ABMR = abbreviated breast MRI, CDR = cancer detection rate, CEM = contrast-enhanced mammography, PPV₂ = positive predictive value 2 (of biopsy recommendation).

CAREGGI : from September 2016
OVER 7500 CEM EXAMS

Nº5967 CEM



- █ Pre-operative Staging
- █ Suspicious Findings
- █ NAC Monitoring
- █ Post-operative
- █ Others Indications

23% of patients: CEM ADDITIONAL LESIONS

Second-look imaging

ECHOGRAPHIE
TOMOSYNTHÈSE 3D



BJR Journal Home Current Issue Latest Articles All Issues Browse By Resources

Home → The British Journal of Radiology → Ahead of Print → Comparison between second-look ultrasound and second-look digital breast tomosynthesis in the detection of additional lesions with presurgical CESM

FULL ACCESS • FULL PAPER

Comparison between second-look ultrasound and second-look digital breast tomosynthesis in the detection of additional lesions with presurgical CESM

Chiara Bellini, Giulia Bicchieri, Francesco Amato, Elena Savi, Diego De Benedetto, Federica Di Naro, Cecilia Boeri, Ermanno Vanzi, Vittorio Miele, and Jacopo Nori


Published Online: 22 Apr 2022 • <https://doi.org/10.1259/bjr.20210927>





Combined second-look imaging DBT + US identified 91.2% of additional lesions that turned out to be malignant at final histology

Second-look imaging

ECHOGRAPHIE



CEM



SAMSUNG

Tissus superficiels /SEIN /LM2-18 /FR18Hz /4.0cm

[2D]

Frq Rés.

GN 51

DR 50

MI 5

P 90

[PD]

Frq Gén.

GN 54

0.73kHz

P 90

[MF]

Frq Gén.

GN 61

0.20kHz

P 90

SAMSUNG

Tissus superficiels /SEIN /LM2-18 /FR50Hz /4.0cm

[2D]

Frq Rés.

GN 51

DR 49

MI 13

P 90



[MF]

Frq Gén.

GN 61

0.20kHz

P 90





IMS
Giotto

GMM
GROUP

SAMSUNG
RS85

SAMSUNG

Tissus superficiels /SEIN /LM2-18 /FR71Hz /4.0cm

[2D]


SAMSUNG
RS85

Frq Rés.
GN 51
DR 50
MI 5
P 100

IM 1.0
ITm 0.3
23-01-2024
14:49:30



0



D1 0.70 cm
D2 0.79 cm

63 y. BI-RADS 5 Right Breast Bifocal




institut du sein
HENRI HARTMANN

BCU
breast cancer units
RIO

Second-look imaging

TOMOSYNTHESIS



Pre-surgical Staging CEM second look



BJR Journal Home Current Issue Latest Articles All Issues Browse By Resources

Home → The British Journal of Radiology → Ahead of Print → Comparison between second-look ultrasound and second-look digital breast tomosynthesis in the detection of additional lesions with presurgical CESM

FULL ACCESS • FULL PAPER

Comparison between second-look ultrasound and second-look digital breast tomosynthesis in the detection of additional lesions with presurgical CESM

Chiara Bellini ✓, Giulia Bicchieri ✓, Francesco Amato ✓, Elena Savi ✓, Diego De Benedetto ✓, Federica Di Naro ✓, Cecilia Boeri ✓, Ermanno Vanzi ✓, Vittorio Miele ✓ and Jacopo Nori ✓

Published Online: 22 April 2022 • <https://doi.org/10.1259/bjr.20210927>

for the remaining **8.8%** MRI OR CEM-guided biopsies
will be the ONLY POSSIBLE solution

décembre 2019
première biopsie du sein guidée par angio-mammographie à l'IGR

Bibliographie

Editorial > *Eur Radiol.* 2023 Jan;33(1):414-416. doi: 10.1007/s00330-022-09196-2.
Epub 2022 Oct 31.

Contrast-enhanced mammography-guided biopsy: why, when, and where we need it

Simone Schiaffino ¹, Andrea Cozzi ²

> *Eur Radiol.* 2023 Jan;33(1):417-428. doi: 10.1007/s00330-022-09021-w. Epub 2022 Jul 27.

Contrast-enhanced mammography-guided biopsy: technical feasibility and first outcomes

R Alcantara ^{# 1}, M Posso ², M Pitarch ³, N Arenas ³, B Ejarque ³, V Iotti ^{# 4}, G Besutti ^{5 6}

Clinical Trial > *AJR Am J Roentgenol.* 2023 Jun;220(6):826-827. doi: 10.2214/AJR.22.28780.
Epub 2023 Feb 1.

Contrast-Enhanced Mammography-Guided Breast Biopsy: Single-Center Experience

Anat Kornecki ¹, Mousumi Bhaduri ², Nasir Khan ³, Ilanit Ben Nachum ¹, Giulio Muscedere ¹,
Olga Shmuilovich ¹, Kalan Lynn ¹, Eni Nano ¹, Lily Blyth ⁴

12 to 66 lesions

> *Quant Imaging Med Surg.* 2023 Aug 1;13(8):5349-5354. doi: 10.21037/qims-23-137.
Epub 2023 Jun 5.

Contrast-enhanced mammography-guided biopsy: technique and initial outcomes

Ya-Chun Tang ^{1 2}, Yun-Chung Cheung ^{1 2}

> *J Breast Imaging.* 2023 Mar 20;5(2):148-158. doi: 10.1093/jbi/wbac096.

Contrast-enhanced Mammography-guided Biopsy: Initial Trial and Experience

Aneta Kowalski ¹, Dooman Arefan ¹, Marie A Ganott ¹, Kimberly Harnist ¹, Amy E Kelly ¹,
Amy Lu ¹, Bronwyn E Nair ¹, Jules H Sumkin ¹, Adrienne Vargo ¹, Wendie A Berg ¹,
Margarita L Zuley ¹

> *J Clin Med.* 2024 Feb 6;13(4):933. doi: 10.3390/jcm13040933.

Contrast-Enhanced Mammography-Guided Biopsy: Preliminary Results of a Single-Center Retrospective Experience

Matteo Sammarra ¹, Claudia Lucia Piccolo ¹, Marina Sarli ¹, Rita Stefanucci ¹,
Manuela Tommasiello ¹, Paolo Orsaria ², Vittorio Altomare ³, Bruno Beomonte Zobel ^{1 4}



IN
I



CEM GUIDED BIOPSY: our experience with GIOTTO CLASS PRONE TABLE




HENRI HARTMANN

BCU
breast cancer units

RIO


MAIN FEATURES

- Wide biopsy field (11 x 15 cm);
- Multiple available approaches:
vertical, angled, and lateral
- Compatible with all commercial vacuum biopsy



OPERATOR INTERFACE SYSTEM

Raffaello software : easy to use




Historical images
of the study

Needle positioning
interface

Active study images



NEEDLE POSITIONING INTERFACE







NEEDLE SIMULATION

optimal range of biopsy driver angles → best approach to the lesion



NEEDLE POSITIONING INTERFACE



optimal range of biopsy driver angles → best approach to the lesion

institut du sein
HENRI HARTMANN

BCU
BREAST CANCER UNIT
RIO




CAS 1 : CC STANDARD APPROACH

Patiante de 65 ans, antécédent de tumorectomie droite.
Asymétrie focale de densité QSE Droit sur mammo de contrôle.
Indication d'angiommographie




IMS
Giotto

GMM
GROUP




institut du sein
HENRI HARTMANN


BCU
BREAST CANCER UNIT
RIO




EARLY RC



LATE RC




EARLY RC




LATE RC

Patient preparation



Recent and past medical history
(history of allergies, severe adverse reactions...)



Creatinine value for renal function assessment



Informed Consent



Venous access

Venous access




Patient positioning







First check



Decompression/ Contrast Injection





- MDC: non-ionic iodinated contrast (300-400 mg/ml), injected intravenously (antecubital vein of the contralateral arm to the suspected breast) to a patient sitting
- INJECTION: 18 G needle, 1.5 ml/Kg, 3 ml /sec.
 - An automatic injector is preferable (for injection of contrast medium and subsequent 20 mL saline solution)

Acquisition :
2 mn after IV
Simultaneous acquisition High & low energy images
Delay 2 s between 2 acquisitions
Automated recombination
Total exam time : 8-10 mn





Compression/ Dual-Energy Acquisition







Targeting/ Selecting needle



Biopsy (anesthesia and sample collecting)





CLIS lésion B3/b







CASE 2 : LATERAL APPROACH :


Patiente de 58 ans, CCI sein gauche.

N+.



Bilan pré thérapeutique







Accès latéral
sans bras
accessoire



Conclusion & messages à retenir

- **Biopsie sous angiomammographie (CEM)**
 - Alternative à la biopsie sous IRM
 - Technique = Stéréotaxie + CEM
 - Rapide
 - Accessible
 - Visualisation de la cible par CEM
 - Plus spécifique, PPR ++, moins de Faux –
 - Partage de l'information plus facile : RCP
- Second look US et TBD 3D : > 90% des cibles
- **Position allongée (prone position):**
 - **Confort patient +++ et médecin**
 - Salle hybride Giotto Class
 - 2D, 3D TBD, Angiomammographie
 - Biopsie sous stereo, Tomo, Angiomammographie
 - Adaptable à toutes les aiguilles

BREAST CANCER UPDATE

4TH EDITION



SO/UPTOWN HOTEL
UPTOWN TOWER, UPTOWN, 214686
DUBAI-UAE

PROMOTING WOMEN'S HEALTH THROUGH A MULTIDISCIPLINARY APPROACH

SAVE THE DATE
JAN 23-26
2025

Scientific organization
Dr. LUC ROTENBERG
Prof. MUSTAPHA BOUBRIT

Logistics & informations
MURIEL.KLEYER@EQUATOUR.NET
+331 41 04 04 19

www.breastcancerupdate.org



institut du sein
HENRI HARTMANN

BCU
BREAST CANCER UPDATE

RIO

C O N G R È S A N N U E L
SIFEM 2025
12>14 JUIN | CNIT FOREST PARIS



CORINNE BALLEYGUIER & ISABELLE THOMASSIN-NAGGARA

Responsabilité
Eco responsabilité
Sein / Gynécologie
Personnalisation
Innovations
Risque
Eco soins

